Skip to main content
All lobbying filings

BGR GOVERNMENT AFFAIRS

Lobbying for NOVARTIS · Multinational biopharmaceutical company

 Filing 1st Quarter - Report
1st Quarter (Jan 1 - Mar 31) 2026 · District of Columbia · House · Senate · $60,000.00 income · posted Apr 20, 2026

Official filing document

 Bills named in this filing 1
  • HR 1672
    Maintaining Investments in New Innovation Act
 Lobbying activity 2
Health Issues

Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies, EPIC Act; Most Favored Nation (MFN) policy, drug pricing policies

Medicare/Medicaid

Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies and EPIC Act

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem